
CHICAGO, Sept. 16 (UPI) -- The bacteria Clostridium difficile may emerge as the next superbug killing thousands in the United States, Loyola University researchers warn.
Dr. Clifford McDonald of the Centers for Disease Control and Prevention said the infection is a virulent strain of a common intestinal bacteria currently plaguing hospitals that now rivals the superbug Methicillin-resistant staphylococcus aureus, or MRSA, as one of the top emerging disease threats to humans.
"Disease caused by Clostridium difficile can range from nuisance diarrhea to life-threatening colitis that could lead to the surgical removal of the colon, and even death," Dr. Stuart Johnson of Loyola University Chicago Stritch School of Medicine said in a statement. "It's a very hardy strain and it seems to persist."
Clostridium difficile was discovered in 1978 to be the cause of antibiotic-associated diarrhea and colitis. It sickens about 500,000 Americans a year and has reached epidemic proportions in 38 states, but most people have not yet heard of it, Johnson said.
Hospitals in Quebec have been particularly hard hit by Clostridium difficile with about 2,000 deaths in the Canadian province directly attributable to the antibiotic resistant strain between the 2003 and 2004.
|
|
|
|
|
|
| Additional Health News Stories | |
SAN JOSE, Costa Rica, Feb. 13 (UPI) --
A 6.1-magnitude earthquake shook Costa Rica Monday and could be felt as far away as Panama, officials said.
|
LOS ANGELES, Feb. 13 (UPI) --
More than 39 million viewers tuned in to the 54th annual Grammy Awards show in Los Angeles, CBS announced Monday.
|
'Piggyback Bandit' jumping on athletes ... A unique date? Wastewater treatment plant ... Romeo, Juliet make Verona a proposal venue ... Man says transvestite escort cheated him ... Watercooler stories from UPI.
|
ATHENS, Greece, Feb. 13 (UPI) --
Street battles between police and protesters left Athens in flames as Parliament approved a harsh austerity bill early Monday to secure a $173 billion bailout.
|
| Stories | Photos | People | Comments |
View Caption